Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved polatuzumab vedotin-piiq (Polivy, Genentech) with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma and who have an International Prognostic Index (IPI) score of 2 or greater.
Approval was based on POLARIX